الإحصائيات الأساسية
| CIK | 1819704 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MEDIROM Healthcare Technologies Inc. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 28, 2025 |
Medirom’s “REMONY” Certified by MLIT as a Fatigue-Driving Prevention Device Exhibit 99.1 Medirom’s “REMONY” Certified by MLIT as a Fatigue-Driving Prevention Device August 28th, 2025, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”, “we” or “us”) announces that its “REMONY for Driver” remote health management system, developed by its subsidiary MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), has been selected by Japan’s Ministry of Land, Infrastructu |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princ |
|
| August 22, 2025 |
Exhibit 99.1 MEDIROM launches cryptocurrency strategy with next- generation proof of human technology, "World" - Acquires ETH as part of financial strategy - Tokyo, Japan – August 22, 2025 – MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM) (the “Company”, “we” or “us”), which operates a diversified healthcare business, announced its participatio |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princ |
|
| August 20, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces July 2025 Key Performance Indicators (KPIs) Total Customers Served: 76,544 – Sales Per Customer: JPY 7,389 – Customer Repeat Ratio: 77.0% Tokyo/August 20, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princ |
|
| August 1, 2025 |
Exhibit 99.1 MEDIROM Joins the World Network, Embracing Next-Generation Proof of Human Concept Led by ChatGPT Creator Sam Altman Creating new social infrastructure in collaboration with Hakuhodo To promote the spread of World ID in Japan, Verification Device“Orb”will be installed in 100 Re.Ra.Ku relaxation salons. Tokyo, Japan – July 31, 2025 – MEDIROM Healthcare Technologies Inc. (Headquarters: M |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princ |
|
| July 21, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces June 2025 Key Performance Indicators (KPIs) Total Customers Served: 77,715 – Sales Per Customer: JPY 7,266 – Customer Repeat Ratio: 77.3% Tokyo/July 21, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, u |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princip |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princip |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princip |
|
| June 20, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces May 2025 Key Performance Indicators (KPIs) Total Customers Served: 80,631 – Sales Per Customer: JPY 7,100 – Customer Repeat Ratio: 76.3% Tokyo/June 20, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, up |
|
| June 5, 2025 |
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements New York/June 5, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on June 4, 2025, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Comp |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princip |
|
| May 30, 2025 |
Notice of Resolution of the 25th Ordinary General Meeting of Shareholders Held on May 30, 2025 Exhibit 99.1 [Note] This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation. Ticker: MRM May 30, 2025 Ko |
|
| May 30, 2025 |
Specific Health Guidance Service Utilizing the Exhibit 99.1 May 2025 Medirom Group Specific Health Guidance Service Utilizing the “Lav” Healthcare App: Surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals! May 30, 2025, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM,” “we,” “us” or “our”), a holistic healthcare company based in Japan, announces that its subsidiary, MEDIROM MOTHER |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of principa |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Principa |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of principa |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of principa |
|
| May 20, 2025 |
Exhibit 99.2 Preventative Health EMPOWERED Earnings Presentation May 2025 Forward-Looking Statements Certain statements included in this presentation (this “Presentation”) of MEDIROM Healthcare Technologies Inc., a company organized under the laws of Japan (the “Company,” “we,” “us” or “our”), are not historical facts but are forward-looking statements for purposes of the safe harbor provisions un |
|
| May 20, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces 22% Rise in Revenue and 20% Improvement in Earnings for 2024; Webcast to Discuss Financial Results to be held on May 21st, 2025 at 8:30 AM ET TOKYO, May 20, 2025 (GLOBE NEWSWIRE) - MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that for the |
|
| May 20, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces April 2025 Key Performance Indicators (KPIs) Total Customers Served: 75,391 – Sales Per Customer: JPY 7,196 – Customer Repeat Ratio: 77.6% Tokyo/May 20, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, u |
|
| April 29, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) I, Fumitoshi Fujiwara, certify that: 1. I have reviewed this annual report on Form 20-F of Medirom Healthcare Technologies Inc. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| April 29, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) I, Kouji Eguchi, certify that: 1. I have reviewed this annual report on Form 20-F of Medirom Healthcare Technologies Inc. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| April 29, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the filing of the Annual Report on Form 20-F for the year ended December 31, 2024 (the “Report”) by Medirom Healthcare Technologies, Inc. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with |
|
| April 29, 2025 |
Exhibit 2.3 Description of Securities Our ADSs have been trading on The Nasdaq Capital Market under the symbol “MRM” since December 29, 2020. Prior to that date, there was no public trading market for our ADSs. Our initial public offering was priced at $15.00 per share on December 28, 2020. Name of each exchange on which Title of each class Trading Symbol registered American Depositary Shares, eac |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| April 29, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the filing of the Annual Report on Form 20-F for the year ended December 31, 2024 (the “Report”) by Medirom Healthcare Technologies, Inc. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies |
|
| April 25, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces March 2025 Key Performance Indicators (KPIs) Total Customers Served: 77,315 – Sales Per Customer: JPY 7,208 – Customer Repeat Ratio: 77.8% Tokyo/April 26, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princi |
|
| April 23, 2025 |
Exhibit 99.3 Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 12:00 p.m. EST on May 22, 2025) The undersigned registered holder of American Receipts hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, insofar as practicable, to vote or cause to be v |
|
| April 23, 2025 |
Exhibit 99.2 [NOTICE: This is a translation of the Japanese original for reference purposes only, and in the event of any discrepancy, the Japanese original shall prevail.] Voting Form To MEDIROM Healthcare Technologies Inc. I hereby vote on each proposal for the annual general meeting and the class shareholders’ meeting concerning common shareholders of MEDIROM Healthcare Technologies Inc. to be |
|
| March 21, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces February 2025 Key Performance Indicators (KPIs) Total Customers Served: 69,781 – Sales Per Customer: JPY 7,107 – Customer Repeat Ratio: 77.0% Tokyo/March 22, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KP |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| March 17, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing Tokyo, Japan – March 18, 2025 – MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that it has obtained a new unsecured short-term bank loan in the amount of JPY350 millio |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| March 13, 2025 |
Exhibit 99.1 MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$61 Million) March 14th, 2025, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs Inc. (“Moth |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| February 21, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces January 2025 Key Performance Indicators (KPIs) Total Customers Served: 75,451 – Sales Per Customer: JPY 7,145 – Customer Repeat Ratio: 76.4% Tokyo/February 22, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| February 18, 2025 |
MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2024 Under Japanese GAAP Sustained Revenue Growth / Operating Profitability New York – February 18, 2025 – MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary, unaudited consolidated financial results |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| January 29, 2025 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs) Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6% Tokyo/January 30, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| January 21, 2025 |
Completion of Offering and Increase in Registered Capital EXHIBIT 99.1 Completion of Offering and Increase in Registered Capital January 21, 2025, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, announces that, on January 14, 2025, all corporate capital registration procedures under Japanese law wer |
|
| January 21, 2025 |
Exhibit 99.1 MEDIROM MOTHER Labs Provides MOTHER Bracelet®︎ Device and Remote Health Monitoring System, REMONY, to TOPPAN Inc. January 21, 2025, Tokyo, Japan: MEDIROM Healthcare technologies Inc. (NASDAQ: MRM) (“MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, is pleased to announce that its subsidiary, MEDIROM MOTHER Labs In |
|
| December 27, 2024 |
Exhibit 16.1 December 27, 2024 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, D.C. 20549 Re: MEDIROM Healthcare Technologies Inc. Ladies and Gentlemen: We have read the statements in the Form 6-K, dated December 27, 2024, of MEDIROM Healthcare Technologies Inc. (the “Registrant”) and we agree with such statements therein as related to our firm. |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 23, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs) Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5% Tokyo/December 23, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 13, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technology‘s Subsidiary MEDIROM MOTHER Labs Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round · Pre-Money Valuation of JPY9 Billion. · Strategic Investors Indicating Promise of Technology and Growth Potential. · Further Commercialization Expected with Recent Orders for Over 25,000 Units from B2B Sales Channel. December 13th 2024, Tokyo, J |
|
| December 12, 2024 |
MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering TOKYO, JAPAN, December 9, 2024 (GLOBE NEWSWIRE) – MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the pricing of a public offering of 2,860,000 American Depositary Sh |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 12, 2024 |
Exhibit 1.1 UNDERWRITING AGREEMENT between MEDIROM HEALTHCARE TECHNOLOGIES INC. and THINKEQUITY LLC as Representative of the Several Underwriters MEDIROM HEALTHCARE TECHNOLOGIES INC. UNDERWRITING AGREEMENT New York, New York December 9, 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentl |
|
| December 12, 2024 |
MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering Exhibit 99.2 MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering TOKYO, JAPAN, December 11, 2024 (GLOBE NEWSWIRE) – MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 11, 2024 |
Exhibit 99.1 Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) December 11th 2024, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHE |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 MEDIROM Healthcare Technologies Inc. (Name of Issuer) American depositary shares, each representing one common share, no par value (Title of Class of Securities) |
|
| December 10, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-281771 PROSPECTUS 2,860,000 American Depositary Shares Representing 2,860,000 Common Shares MEDIROM Healthcare Technologies Inc. This is a firm commitment public offering of common shares of MEDIROM Healthcare Technologies Inc. represented by American Depositary Shares, or ADSs. Each ADS represents one common share, no par v |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 9, 2024 |
December 9, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 9, 2024 |
MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units Exhibit 99.1 MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units December 9th 2024, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc. “Our long-term |
|
| December 9, 2024 |
December 9, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N. |
|
| December 6, 2024 |
Exhibit 99.1 M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation TOKYO, Dec. 02, 2024 (GLOBE NEWSWIRE) - MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| December 4, 2024 |
Exhibit 1.1 UNDERWRITING AGREEMENT between MEDIROM HEALTHCARE TECHNOLOGIES INC. and THINKEQUITY LLC as Representative of the Several Underwriters MEDIROM HEALTHCARE TECHNOLOGIES INC. UNDERWRITING AGREEMENT New York, New York [●], 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: T |
|
| December 4, 2024 |
As filed with the U.S. Securities and Exchange Commission on December 4, 2024. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on December 4, 2024. Registration No. 333-281771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of Registrant as specified in its Charter) Japan 8000 Not Applicable ( |
|
| December 4, 2024 |
Exhibit 4.9 December 3, 2024 To: MEDIROM Healthcare Technologies Inc. 1-4-28 Mita, Minato-ku, Tokyo Kufu Company Inc. Yoshiteru Akita, Representative Director [Stamped Seal] Notice Regarding the First Unsecured Convertible-Type Corporate Bonds with Share Options of MEDIROM Healthcare Technologies Inc. issued by your company on December 28, 2022 (the “Convertible Bonds”), notwithstanding the provis |
|
| December 2, 2024 |
As filed with the U.S. Securities and Exchange Commission on December 2, 2024. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on December 2, 2024. Registration No. 333-281771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of Registrant as specified in its Charter) Japan 8000 Not Applicable ( |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| November 21, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces October 2024 Key Performance Indicators (KPIs) Total Customers Served: 79,571 – Sales Per Customer: JPY 6,923 – Customer Repeat Ratio: 76.6% Tokyo/November 21, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| November 8, 2024 |
Exhibit 4.1 November 1, 2024 To: Kufu Company Inc. 2-3-1 Daiba, Minato-ku, Tokyo MEDIROM Healthcare Technologies Inc. Kouji Eguchi, Representative Director [Stamped seal] Letter of Proposal In connection with the 1st Unsecured Convertible-Type Corporate Bonds with Share Options of MEDIROM Healthcare Technologies Inc. issued to you on December 28, 2022 (the “Convertible Bonds”), we hereby propose a |
|
| November 8, 2024 |
INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Financial Statements as of June 30, 2024 and for the Six Months Ended June 30, 2024 and 2023 Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 F-2 Condensed Consolidated Statements of Loss for the Six Months Ended June 30, 2024 and |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pri |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) MEDIROM HEALTHCARE TECHNOLOGIES INC. |
|
| November 7, 2024 |
[*****] INDICATES THAT INFORMATION HAS BEEN REDACTED Memorandum of Understanding Exhibit 10.6 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [*****] INDICATES THAT INFORMATION HAS BEEN REDACTED Memorandum of Understanding Shinji Noguchi (hereinafter referred to as “Seller”), MEDIROM Healthcare Technologies Inc. (hereinafter referred to as “Buyer”) and Japan Gene Medicine Corporation (hereinafter refe |
|
| November 7, 2024 |
Exhibit 4.5 November 1, 2024 To: Kufu Company Inc. 2-3-1 Daiba, Minato-ku, Tokyo MEDIROM Healthcare Technologies Inc. Kouji Eguchi, Representative Director [Stamped seal] Letter of Proposal In connection with the 1st Unsecured Convertible-Type Corporate Bonds with Share Options of MEDIROM Healthcare Technologies Inc. issued to you on December 28, 2022 (the “Convertible Bonds”), we hereby propose a |
|
| November 7, 2024 |
Exhibit 1.1 UNDERWRITING AGREEMENT between MEDIROM HEALTHCARE TECHNOLOGIES INC. and THINKEQUITY LLC as Representative of the Several Underwriters MEDIROM HEALTHCARE TECHNOLOGIES INC. UNDERWRITING AGREEMENT New York, New York [●], 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: T |
|
| November 7, 2024 |
[*****] INDICATES THAT INFORMATION HAS BEEN REDACTED Share Transfer Agreement June 30, 2024 Exhibit 10.5 CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K, BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. [*****] INDICATES THAT INFORMATION HAS BEEN |
|
| November 7, 2024 |
As filed with the U.S. Securities and Exchange Commission on November 7, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on November 7, 2024. Registration No. 333-281771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of Registrant as specified in its Charter) Japan 8000 Not Applicable ( |
|
| October 24, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces September 2024 Key Performance Indicators (KPIs) Total Customers Served: 82,401 – Sales Per Customer: JPY 7,158 – Customer Repeat Ratio: 75.8% Tokyo/October 24, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| October 15, 2024 |
Exhibit 99.1 ELEMATEC CORPORATION FORMS A BUSINESS ALLIANCE WITH AND AGREES TO MAKE A STRATEGIC INVESTMENT IN MEDIROM HEALTHCARE TECHNOLOGIES’ MOTHER LABS SUBSIDIARY OCTOBER 15th, 2024, Tokyo, Japan: MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. has formed a capital and business alliance with Elematec Corporation (TOKYO PRIME: 2715), a me |
|
| October 11, 2024 |
Exhibit 4.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K. MEDIROM Healthcare Technologies Inc. 2nd Unsecured Convertible-Type Corporate Bonds with Share Options PURCHASE AGREEMENT This Purchase Agreement (hereinafter referred to as the “Agreement”) was made and entered into as of October 8, 2024, by an |
|
| October 11, 2024 |
Exhibit 4.2 Terms of 2nd Unsecured Convertible-Type Corporate Bonds with Share Options of MEDIROM Healthcare Technologies Inc. 1. Name of the Securities The name of the securities is the 2nd Unsecured Convertible-Type Corporate Bonds with Share Options (hereinafter referred to as the “CB”, the bond portion of which is hereinafter referred to as the “Bond” and the share option portion of which is h |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| September 25, 2024 |
Skadden, Arps, Slate, Meagher & Flom llp One Manhattan West FIRM/AFFILIATE New York, NY 10001 OFFICES - - TEL: (212) 735-3000 BOSTON FAX: (212) 735-2000 CHICAGO www. |
|
| September 24, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces August 2024 Key Performance Indicators (KPIs) Total Customers Served: 83,771 – Sales Per Customer: JPY 7,144 – Customer Repeat Ratio: 75.1% Tokyo/September 24, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of pr |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princ |
|
| August 27, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces July 2024 Key Performance Indicators (KPIs) Total Customers Served: 81,580 – Sales Per Customer: JPY 7,060 – Customer Repeat Ratio: 75.0% Tokyo/August 27, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, |
|
| August 23, 2024 |
Exhibit 99.1 Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Koji Eguchi; listed on Nasdaq, NASDAQ: MRM; hereinafter “MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku |
|
| August 23, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of the Registrant Legal Name of the Subsidiary Jurisdiction MEDIROM Shared Services Inc. Japan WING Inc. Japan JOYHANDS WELLNESS Inc. Japan Medirom Human Resources Inc. Japan SAWAN CO. LTD. Japan ZACC Kabushiki Kaisha Japan MEDIROM MOTHER Labs Inc. Japan MEDIROM Rehab Solutions Inc. Japan |
|
| August 23, 2024 |
Articles of Incorporation of Kabushiki Kaisha MEDIROM Chapter I General Provisions Exhibit 3.1 Articles of Incorporation of Kabushiki Kaisha MEDIROM Chapter I General Provisions Article 1 (Company Name) The company name of this company is “Kabushiki Kaisha MEDIROM”, which is expressed in English as “MEDIROM Healthcare Technologies Inc” (hereinafter referred to as “the Company”). Article 2 (Purposes) The purposes of the Company are to engage in the following businesses: 1. genera |
|
| August 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) MEDIROM HEALTHCARE TECHNOLOGIES INC. |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princ |
|
| August 23, 2024 |
As filed with the U.S. Securities and Exchange Commission on August 23, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on August 23, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of Registrant as specified in its Charter) Japan 8000 Not Applicable (State or other jurisdictio |
|
| July 23, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces June 2024 Key Performance Indicators (KPIs) Total Customers Served: 82,656 – Sales Per Customer: JPY 7,061 – Customer Repeat Ratio: 75.6% Tokyo/July 23, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, u |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princip |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princip |
|
| July 10, 2024 |
Medirom Healthcare Technologies Announces Acquisition of Japan Gene Medicine Corporation Exhibit 99.1 Medirom Healthcare Technologies Announces Acquisition of Japan Gene Medicine Corporation New York/July 10, 2024 - MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that the Company plans to acquire a majority of Japan Gene Medicine Corporation (the “Target Company”). On June 30, 2024, the Company entered into a share transfer agreement (the "Sh |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princip |
|
| June 25, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces May 2024 Key Performance Indicators (KPIs) Total Customers Served: 80,512 – Sales Per Customer: JPY 6,964 – Customer Repeat Ratio: 74.8% Tokyo/June 25, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, up |
|
| June 25, 2024 |
MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023 Exhibit 99.2 MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023 Tokyo, Japan, June 25, 2024 (GLOBE NEWSWIRE) - MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”), a holistic healthcare company based in Japan, announced it filed its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Co |
|
| June 18, 2024 |
MEDIROM HEALTHCARE TECHNOLOGIES INC. 2024 EQUITY INCENTIVE COMPENSATION PLAN Exhibit 4.4 MEDIROM HEALTHCARE TECHNOLOGIES INC. 2024 EQUITY INCENTIVE COMPENSATION PLAN 1.Purpose; Eligibility. 1.1General Purpose. The name of this plan is the MEDIROM Healthcare Technologies Inc. 2024 Equity Incentive Compensation Plan (the “Plan”). The purposes of the Plan are to (a) enable MEDIROM Healthcare Technologies Inc., a Japanese joint-stock corporation (the “Company”), and any Affili |
|
| June 18, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) I, Kouji Eguchi, certify that: 1. I have reviewed this annual report on Form 20-F of Medirom Healthcare Technologies Inc. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| June 18, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the filing of the Annual Report on Form 20-F for the year ended December 31, 2023 (the “Report”) by Medirom Healthcare Technologies, Inc. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies |
|
| June 18, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) I, Fumitoshi Fujiwara, certify that: 1. I have reviewed this annual report on Form 20-F of Medirom Healthcare Technologies Inc. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| June 18, 2024 |
Exhibit 97.1 MEDIROM HEALTHCARE TECHNOLOGIES INC. Executive Officer Clawback Policy Approved by the Board of Directors on November 28, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of MEDIROM Healthcare Technologies Inc. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or |
|
| June 18, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the filing of the Annual Report on Form 20-F for the year ended December 31, 2023 (the “Report”) by Medirom Healthcare Technologies, Inc. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of principa |
|
| May 21, 2024 |
MEDIROM Healthcare Technologies Inc. Receives Notification from Nasdaq Related to Annual Report Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Receives Notification from Nasdaq Related to Annual Report New York/May 21, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a leading holistic health services provider in Japan (the “Company”), today announced that on May 20, 2024, as a result of its failure to timely file with the U.S. Securities and Exchange Commission (the “SEC”) it |
|
| May 21, 2024 |
Exhibit 99.2 MEDIROM Healthcare Technologies Inc. Announces April 2024 Key Performance Indicators (KPIs) Total Customers Served: 74,621 – Sales Per Customer: JPY 7,143 – Customer Repeat Ratio: 75.9% Tokyo/May 21, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, u |
|
| April 30, 2024 |
SEC FILE NUMBER: 001-39809 CUSIP NUMBER: 58510H103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs) Total Customers Served: 77,854 – Sales Per Customer: JPY 7,190 – Customer Repeat Ratio: 77.9% Tokyo/April 24, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| April 2, 2024 |
Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization) Exhibit 99.1 Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization) 2-3-1 Daiba, Minato-ku, Tokyo MEDIROM Healthcare Technologies Inc. New York/April 2, 2024 - MEDIROM Healthcare Technologies Inc. (“we”, “our” or “us”) hereby announces that we resolved, at a meeting of our Board of Directors held on March 29, 2024, to enter into a Memorandum of Understanding |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princi |
|
| March 29, 2024 |
Notice of Resolution of the 24th Ordinary General Meeting of Shareholders Held on March 29, 2024 Exhibit 99.1 【Note】 This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation. Ticker: MRM March 29, 2024 |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| March 21, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces February 2024 Key Performance Indicators (KPIs) Total Customers Served: 71,376 – Sales Per Customer: JPY 7,099 – Customer Repeat Ratio: 77.6% Tokyo/March 21, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KP |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japa |
|
| March 15, 2024 |
Exhibit 99.4 March 15, 2024 MEDIROM Healthcare Technologies Inc. (CORRECTION) Fiscal Year 2023 Business Report, Annex A to Notice of Convocation of the 24th Ordinary General Meeting of Shareholders MEDIROM Healthcare Technologies Inc. (the “Company”) hereby announces that there have been corrections to the Company’s Fiscal Year 2023 Business Report (the “Business Report”) attached as Annex A to th |
|
| March 11, 2024 |
Exhibit 99.3 24-6880 Medirom VIF Proof 7 Please separate carefully at the perforation and return just this portion in the envelope provided. Please Sign Here Please Date Above Please Sign Here Please Date Above Authorized Signatures - This section must be completed for your instructions to be executed. Annual General Meeting of MEDIROM Healthcare Technologies Inc. to be held March 29, 2024 For |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princi |
|
| March 11, 2024 |
Exhibit 99.2 [NOTICE: This is a translation of the Japanese original for reference purposes only, and in the event of any discrepancy, the Japanese original shall prevail.] Voting Form To MEDIROM Healthcare Technologies Inc. I hereby vote on each proposal for the annual general meeting of MEDIROM Healthcare Technologies Inc. to be held on Friday, March 29, 2024, as indicated by the circle below. I |
|
| March 11, 2024 |
[English Translation of Convocation Notice Originally Issued in the Japanese Language] 1 【Note】 This document has been translated from the Japanese original for reference purposes only. |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Pri |
|
| February 22, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces January 2024 Key Performance Indicators (KPIs) Total Customers Served: 74,533 – Sales Per Customer: JPY 7,147 – Customer Repeat Ratio: 76.8% New York/February 22, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Prin |
|
| January 25, 2024 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces December 2023 Key Performance Indicators (KPIs) Total Customers Served: 83,124 – Sales Per Customer: JPY 7,271 – Customer Repeat Ratio: 77.7% New York/January 25, 2024 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Pri |
|
| December 29, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Reports Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update New York – December 29, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM) (“MEDIROM” or the “Company”), a leading holistic health services provider in Japan, today announced its interim financial results for the six months ended June 30, 2023. P |
|
| December 22, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces November 2023 Key Performance Indicators (KPIs) Total Customers Served: 75,290 – Sales Per Customer: JPY 7,045 – Customer Repeat Ratio: 77.5% New York/December 22, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Pri |
|
| November 24, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces October 2023 Key Performance Indicators (KPIs) Total Customers Served: 82,249 – Sales Per Customer: JPY 6,891 – Customer Repeat Ratio: 77.4% New York/November 24, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Pri |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Prin |
|
| October 25, 2023 |
Exhibit 99.1 NASDAQ: MRM September, 2023 Important Notices IMPORTANT NOTICES AND DISCLAIMERS This investor presentation (this “Investor Presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities of MEDIROM Hea lt hcare Technologies Inc., a company organized under |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Prin |
|
| October 24, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces September 2023 Key Performance Indicators (KPIs) Total Customers Served: 84,393 – Sales Per Customer: JPY 6,991 – Customer Repeat Ratio: 76.7% New York/October 24, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| October 3, 2023 |
7th Series Stock Option Allotment Agreement Exhibit 4.5 7th Series Stock Option Allotment Agreement In accordance with the resolutions at the special meeting of shareholders held on December 21, 2016 and the meeting of the board of directors held on December 21, 2016 (the "Resolutions"), this agreement (this “Agreement”) has been entered into between Re.Ra.Ku Inc. (the "Company") and [ ] (the "Grantee") in connection with stock option under |
|
| October 3, 2023 |
Articles of Incorporation of Kabushiki Kaisha MEDIROM Chapter I General Provisions Exhibit 4.1 Articles of Incorporation of Kabushiki Kaisha MEDIROM Chapter I General Provisions Article 1 (Company Name) The company name of this company is “Kabushiki Kaisha MEDIROM”, which is expressed in English as “MEDIROM Healthcare Technologies Inc” (hereinafter referred to as “the Company”). Article 2 (Purposes) The purposes of the Company are to engage in the following businesses: 1. genera |
|
| October 3, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Medirom Healthcare Technologies Inc. |
|
| October 3, 2023 |
9th Series Stock Option Allotment Agreement Exhibit 4.7 9th Series Stock Option Allotment Agreement In accordance with the resolutions at the special meeting of shareholders and the meeting of the class A shareholder held on August 31, 2020 and the meeting of the board of directors held on October 2, 2020 (the "Resolutions"), this Stock Option Allotment Agreement (this “Agreement”) has been entered into between MEDIROM Healthcare Technologi |
|
| October 3, 2023 |
5th Series Stock Option Allotment Agreement Exhibit 4.4 5th Series Stock Option Allotment Agreement In accordance with the resolutions at the special meeting of shareholders held on December 21, 2015 and the meeting of the board of directors held on December 21, 2015 (the "Resolutions"), this agreement (this “Agreement”) has been entered into between Re.Ra.Ku Inc. (the "Company") and [ ] (the "Grantee") in connection with stock option under |
|
| October 3, 2023 |
As filed with the Securities and Exchange Commission on October 2, 2023 As filed with the Securities and Exchange Commission on October 2, 2023 Registration No. |
|
| October 3, 2023 |
8th Series Stock Option Allotment Agreement Exhibit 4.6 8th Series Stock Option Allotment Agreement In accordance with the resolutions at the special meeting of shareholders and the meeting of the class A shareholder held on August 31, 2020 and the meeting of the board of directors held on October 2, 2020 (the "Resolutions"), this Stock Option Allotment Agreement (this “Agreement”) has been entered into between MEDIROM Healthcare Technologi |
|
| September 20, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces August 2023 Key Performance Indicators (KPIs) Total Customers Served: 87,224 – Sales Per Customer: JPY 6,946 – Customer Repeat Ratio: 74.6% New York/September 20, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Pr |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princ |
|
| August 22, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces July 2023 Key Performance Indicators (KPIs) Total Customers Served: 88,240 – Sales Per Customer: JPY 6,985 – Customer Repeat Ratio: 76.0% New York/August 22, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KP |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princip |
|
| July 20, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces June 2023 Key Performance Indicators (KPIs) Total Customers Served: 81,280 – Sales Per Customer: JPY 6,801 – Customer Repeat Ratio: 76.0% New York/July 20, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs |
|
| June 20, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces May 2023 Key Performance Indicators (KPIs) Total Customers Served: 86,895 – Sales Per Customer: JPY 6,660 – Customer Repeat Ratio: 75.7% New York/June 20, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princip |
|
| June 5, 2023 |
Incorporation-type Company Split Plan Exhibit 10.1 Incorporation-type Company Split Plan This Incorporation-type Company Split Plan (hereinafter referred to as this “Plan”) is made by MEDIROM Healthcare Technologies Inc. (hereinafter referred to as the "Company") for the purpose to implement the company split (hereinafter referred to as the " Company Split") in accordance with which MEDIROM MOTHER Labs Inc., the newly established comp |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princip |
|
| June 5, 2023 |
Absorption-type Company Split Agreement Exhibit 10.2 Absorption-type Company Split Agreement This Absorption-type Company Split Agreement (hereinafter referred to as this “Agreement”) is entered into between Bell & Joy Power Partners Inc. (hereinafter referred to as "BJPP") and MEDIROM Healthcare Technologies Inc. (hereinafter referred to as "MEDIROM") as follows: Article 1 (Absorption-type Company Split) BJPP and MEDIROM shall implemen |
|
| June 5, 2023 |
MEDIROM Healthcare Technologies Inc. Announces Group Reorganization Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Group Reorganization New York/June 2, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that at a meeting of the Board of Directors held on May 31, 2023, the Board approved a reorganization of the Company, where the Company will transfer |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princip |
|
| June 2, 2023 |
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements New York/June 2, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on June 1, 2023, the Nasdaq Hearing Panel (the “Panel”) notified the Company that it has regained compliance with |
|
| May 30, 2023 |
SECOND AMENDMENT TO DEVELOPMENT AND PRODUCTION AGREEMENT Exhibit 10.2 SECOND AMENDMENT TO DEVELOPMENT AND PRODUCTION AGREEMENT This Second Amendment to the Development and Production Agreement dated August 4, 2020 (the “Second Amendment”) is made and entered into, effective as of December 8th, 2022 (the “Effective Date”), by and between Matrix Industries, Inc., a Delaware Corporation with a place of business at 1440 O’Brien Drive, Suite A-1, Menlo Park, |
|
| May 30, 2023 |
MEDIROM HEALTHCARE TECHNOLOGIES INC. POLICY ON INSIDER TRADING AND DISCLOSURE EX-11.2 3 mrm-20221231xex11d2.htm EX-11.2 Exhibit 11.2 MEDIROM HEALTHCARE TECHNOLOGIES INC. POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Medirom Healthcare Technologies Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company and supplements |
|
| May 30, 2023 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the filing of the Annual Report on Form 20-F for the year ended December 31, 2022 (the “Report”) by Medirom Healthcare Technologies, Inc. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with |
|
| May 30, 2023 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) I, Kouji Eguchi, certify that: 1. I have reviewed this annual report on Form 20-F of Medirom Healthcare Technologies Inc. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| May 30, 2023 |
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 In connection with the filing of the Annual Report on Form 20-F for the year ended December 31, 2022 (the “Report”) by Medirom Healthcare Technologies, Inc. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies |
|
| May 30, 2023 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) I, Fumitoshi Fujiwara, certify that: 1. I have reviewed this annual report on Form 20-F of Medirom Healthcare Technologies Inc. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| May 24, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces NASDAQ Grants Request for Further Extension to Demonstrate Compliance with Net Income Standard, and Receives NASDAQ Notification Related to Delayed Filing of Annual Report New York/May 24, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Principa |
|
| May 22, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces April 2023 Key Performance Indicators (KPIs) Total Customers Served: 83,130 – Sales Per Customer: JPY 6,669 – Customer Repeat Ratio: 77.0% New York/May 22, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Principa |
|
| May 1, 2023 |
6-K 1 tm2314203d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 1 |
|
| May 1, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces the Company’s Request for an Extension until May 19, 2023, to Demonstrate Compliance Has Been Granted By NASDAQ New York/May 1, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on April 28, 2023, it received a written notice from th |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39809 CUSIP NUMBER 58510H103 (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tra |
|
| April 20, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces March 2023 Key Performance Indicators (KPIs) Total Customers Served: 78,063 – Sales Per Customer: JPY 6,680 – Customer Repeat Ratio: 77.4% New York/April 20, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KP |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princi |
|
| March 31, 2023 |
Notice of Resolution of the 23rd Ordinary General Meeting of Shareholders held on March 31, 2023 Exhibit 99.1 【Note】 This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation. Ticker: MRM March 31, 2023 |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Princi |
|
| March 27, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces February 2023 Key Performance Indicators (KPIs) Total Customers Served: 71,707 – Sales Per Customer: JPY 6,612 – Customer Repeat Ratio: 78.5% New York/March 27, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or |
|
| March 16, 2023 |
[English Translation of Convocation Notice Originally Issued in the Japanese Language] Exhibit 99.1 [English Translation of Convocation Notice Originally Issued in the Japanese Language] [Note] This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail. The Company assumes no responsibility for this translation or for direct, |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| March 16, 2023 |
Exhibit 99.2 Annual General Meeting of MEDIROM Healthcare Technologies Inc. Date: March 31, 2023 See Voting Instruction On Reverse Side. Please make your marks like this: X? Use pen only Agenda: For Against Proposal 1: To amend the Articles of Incorporation ? ? Proposal 2: To reduce the registered paid-in capital and ? ? additional reserved capital (those of which will be reclassified to other cap |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of princi |
|
| March 16, 2023 |
MEDIROM Healthcare Technologies Inc. Successfully Appeals Nasdaq Delisting Notice Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Successfully Appeals Nasdaq Delisting Notice New York/March 16, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on March 15, 2023, it received a written notice from the Nasdaq Hearing Panel (the “Panel”) granting the Company’s request for co |
|
| February 22, 2023 |
6-K 1 tm237363d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo |
|
| February 22, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces January 2023 Key Performance Indicators (KPIs) Total Customers Served: 77,657 – Sales Per Customer: JPY 6,624 – Customer Repeat Ratio: 77.9% New York/February 22, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| January 25, 2023 |
US58510H1032 / MEDIROM Healthcare Technologies Inc / Eguchi Kouji - SC 13D Activist Investment SC 13D 1 tm234310d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* MEDIROM Healthcare Technologies Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 58510H103** (CUSIP Number) Kouji Eguchi c/o COZY LLC 3-5-1 Itabashi, Itabashi-ku Tokyo, Japan +8 |
|
| January 25, 2023 |
EX-99.1 2 tm234310d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL, (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED, AND (III) IS THE TYPE OF INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Issuer Name: MEDIROM Healthcar |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of prin |
|
| January 19, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Up to JPY 50 Million Stock Repurchase Plan by its Controlling Shareholder and CEO New York/January 19, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that COZY LLC (“COZY”), a company owned and controlled by Mr. Kouji Eguchi, the CEO a |
|
| January 18, 2023 |
Exhibit 99.2 MEDIROM Healthcare Technologies Inc. Announces December 2022 Key Performance Indicators (KPIs) Total Customers Served: 66,571 – Sales Per Customer: JPY 6,913 – Customer Repeat Ratio: 82.8% New York/January 18, 2023 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2023 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Prin |
|
| January 18, 2023 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2022 under Japanese GAAP Continuous Strong Revenue Growth / Turned into Operating Profitability New York – January 18, 2023 – MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary, unaudited |
|
| January 11, 2023 |
January 11, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Brian Fetterolf Re: Medirom Healthcare Technologies Inc. Request to Withdraw Registration Statement on Form F-1 File No. 333-262766 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Medi |
|
| January 6, 2023 |
US58510H1032 / MEDIROM Healthcare Technologies Inc / Kufu Co Inc. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) MEDIROM Healthcare Technologies Inc. (Name of Issuer) American depositary shares, each representing one common share, no par value (Title of Class of Securities) 58510H103 (CUSIP Number) Jun Kanma c/o Kufu Company, Inc. Mita Kokusai Bldg. 23F, 1-4-28 Mita, |
|
| December 30, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Receipt of Nasdaq Delisting Notice and Intends to Request a Hearing to Appeal the Delisting Determination New York/December 30, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced that on December 28, the Company received a written notice (the ?Notice?) |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant?s name into English) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of Pri |
|
| December 29, 2022 |
6-K 1 tm2233500d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Translation of registrant’s name into English) 2-3-1 Daiba, Minato-ku Toky |
|
| December 29, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Closing of Sale and Issuance of Convertible Corporate Bonds to Kufu Company Inc. New York/December 29, 2022 ? MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced that it had closed its previously announced sale and issuance (the ?Transaction?) of JPY500,000,0 |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| December 27, 2022 |
Exhibit 99.1 December 27, 2022 MEDIROM Healthcare Technologies Inc. Reports Financial Results for the Six Months Ending June 30, 2022 and Provides Corporate Update New York – December 27, 2022 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM, “MEDIROM” or the “Company”), a leading holistic health services provider in Japan, today announced its interim financial results for the six months ende |
|
| December 21, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Sets Full Year 2021 Earnings Call for Thursday, December 22, 2022, at 4:00 p.m. ET New York/December 21, 2022 ? MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the ?Company?), announced today that the Company will hold a conference call on Thursday, December 22, 2022, at 4:00 p.m. Eastern Time (1 |
|
| December 21, 2022 |
Preventative Health EMPOWERED Earnings Presentation December 2022 Exhibit 99.2 Preventative Health EMPOWERED Earnings Presentation December 2022 Notices & Disclaimers Forward Looking Statements 02 Certain statements included in this presentation are not historical facts but are forward - looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995 . Forward - looking statements may include |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| December 20, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces November 2022 Key Performance Indicators (KPIs) Total Customers Served: 65,724 ? Sales Per Customer: JPY 6,717 ? Customer Repeat Ratio: 82.6% New York/December 20, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced its major Key Performance Indicators, |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| December 16, 2022 |
Letter of Baker Tilly US, LLP, dated December 16, 2022 Exhibit 16.1 December 16, 2022 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, D.C. 20549 Re: MEDIROM Healthcare Technologies Inc. Ladies and Gentlemen: We have read the statements in the Form 6-K, dated December 16, 2022, of MEDIROM Healthcare Technologies Inc. (the ?Registrant?) and we agree with such statements therein as related to our firm. |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| December 9, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Proposed Sale of Convertible Corporate Bonds and Capital Alliance with Kufu Company Inc. New York/December 9, 2022 ? MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced the entry into the First Unsecured Convertible-Type Corporate Bonds with Share Options Pur |
|
| December 9, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces Preliminary Interim Half-Year Financial Results in 2022 Revenue growth of 47.9% / Total Gross Margin 26.6% New York – December 9, 2022 – MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary unaudited financial results for the interim half-year |
|
| December 9, 2022 |
Indenture, dated December 9, 2022 [English Translation] Exhibit 4.2 Terms of 1st Unsecured Convertible-Type Corporate Bonds with Share Options of MEDIROM Healthcare Technologies Inc. 1. Name of Securities The name of securities is 1st Unsecured Convertible-Type Corporate Bonds with Share Options (hereinafter referred to as the ?CB?, the bond portion of which is hereinafter referred to as the ?Bond? and the share option portion of which is hereinafter r |
|
| December 9, 2022 |
EX-10.1 4 tm2232319d2ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL, (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED, AND (III) IS THE TYPE OF INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Capital Alliance Agreement The Ca |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| December 9, 2022 |
6-K 1 tm2232319d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato- |
|
| December 9, 2022 |
Exhibit 4.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL, (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED, AND (III) IS THE TYPE OF INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. MEDIROM Healthcare Technologies Inc. 1st Unsecured Convertible-Type Corporate B |
|
| November 23, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces October 2022 Key Performance Indicators (KPIs) Total Customers Served: 72,252 – Sales Per Customer: JPY 6,630 – Customer Repeat Ratio: 81.8% New York/November 23, 2022 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| November 14, 2022 |
Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith. Exhibit 13.2 ? CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 ? In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2021 (the ?Report?) by Medirom Healthcare Technologies, Inc. (the ?Company?), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: ? (1) the Report fully compl |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| November 14, 2022 |
Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith. Exhibit 13.1 ? CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 ? In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2021 (the ?Report?) by Medirom Healthcare Technologies, Inc. (the ?Company?), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: ? (1) the Report fully c |
|
| November 14, 2022 |
Exhibit 12.1 ? CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) ? I, Kouji Eguchi, certify that: ? 1. I have reviewed this annual report on Form 20?F of Medirom Healthcare Technologies, Inc.; ? 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| November 14, 2022 |
Exhibit 12.2 ? CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) ? I, Fumitoshi Fujiwara, certify that: ? 1. I have reviewed this annual report on Form 20?F of Medirom Healthcare Technologies, Inc.; ? 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| October 20, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces September 2022 Key Performance Indicators (KPIs) Total Customers Served: 71,770 ? Sales Per Customer: JPY 6,505 ? Customer Repeat Ratio: 80.8% New York/October 20, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced its major Key Performance Indicators, |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address |
|
| September 20, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces August 2022 Key Performance Indicators (KPIs) Total Customers Served: 72,250 ? Sales Per Customer: JPY 6,705 ? Customer Repeat Ratio: 80.1% New York/September 20, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced its major Key Performance Indicators, |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Addres |
|
| August 22, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces July 2022 Key Performance Indicators (KPIs) Total Customers Served: 76,521 ? Sales Per Customer: JPY 6,511 ? Customer Repeat Ratio: 80.6% New York/August 22, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced its major Key Performance Indicators, or KP |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address o |
|
| July 22, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces June 2022 Key Performance Indicators (KPIs) Total Customers Served: 73,259 ? Sales Per Customer: JPY 6,511 ? Customer Repeat Ratio: 80.4% New York/July 22, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced its major Key Performance Indicators, or KPIs |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of |
|
| July 1, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Receives Nasdaq Notification Regarding Minimum Market Value Deficiency New York/July 1, 2022 ? MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare Company based in Japan (the ?Company?), announced today that it has received a written notification (the ?Notification Letter?) from The Nasdaq Stock Market LLC (?Nasdaq?) dated |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of P |
|
| June 21, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces May 2022 Key Performance Indicators (KPIs) Total Customers Served: 77,291 – Sales Per Customer: JPY 6,461 – Customer Repeat Ratio: 79.6% New York/June 21, 2022 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number 001-39809 MEDIROM HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan (Address of P |
|
| May 19, 2022 |
Exhibit 99.1 MEDIROM Healthcare Technologies Inc. Announces April 2022 Key Performance Indicators (KPIs) Total Customers Served: 69,986 ? Sales Per Customer: JPY 6,616 ? Customer Repeat Ratio: 82.0% New York/May 19, 2022 ? MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the ?Company?), today announced its major Key Performance Indicators, or KPIs |
